COVID-19
COVID-19 treatments: authorised
Treatments authorised in the European Union (EU) to treat COVID-19, following evaluation by the European Medicines Agency (EMA).
The following treatments can be used in the EU to treat COVID-19:
| Treatment | Status | More information |
|---|---|---|
| Evusheld (tixagevimab / cilgavimab) | Marketing authorisation granted: 25/03/2022 | Latest news |
| Kineret (anakinra) | Marketing authorisation granted: 17/12/2021 | Latest news |
| Paxlovid (PF-07321332 / ritonavir) | Conditional marketing authorisation granted: 28/01/2022 | |
| RoActemra | Marketing authorisation for COVID-19 indication granted: 07/12/2021 | Latest news |
| Veklury (remdesivir) |
Marketing authorisation granted: 08/08/2022 Conditional marketing authorisation granted: 03/07/2020 |
Clinical data (login required) |
| Regkirona (regdanvimab) | Marketing authorisation granted: 12/11/2021 | |
| Ronapreve (casirivimab / imdevimab) | Marketing authorisation granted: 12/11/2021 | Latest news |
| Xevudy (sotrovimab) | Marketing authorisation granted: 17/12/2021 | Latest news |
For more information on how EMA fast-tracks its evaluation of promising potential COVID-19 medicines, see: